Immunogenicity using a combination of dna and vaccinia virus vector vaccines

• US 20040033237A1
• Filed: 10/25/2002
• Published: 02/19/2004
• Est. Priority Date: 04/28/2000
• Status: Active Grant

• Current Assignee: Health and Human Services United States of America As Represented By The SEC, Aventis Pasteur Inc. (Sanofi )
• Original Assignee: Health and Human Services United States of America As Represented By The SEC, Aventis Pasteur Inc. (Sanofi )
• Inventors: Franchini, Genoveffa, Pavlakis, George, Hel, Zdenek
• Granted Patent: US 7,094,408 B2
• Time in Patent Office: Days
• US Class Current: 424/199.1
• CPC Class Codes: A61K 2039/5256 expressing foreign proteins
• CPC Class Codes: A61K 2039/53 DNA (RNA) vaccination
• CPC Class Codes: A61K 2039/54 characterised by the route of administration
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 39/21 Retroviridae, e.g. equine infectious anemia virus
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/24043 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2710/24143 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2740/15022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2740/15034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2740/16034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2740/16122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2740/16222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2740/16322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: Y10S 530/826 Viruses

Abstract

This invention relates to improved methods of inducing an immune response for the prevention or treatment of HIV-1 infection by using a nucleic acid vaccine in conjunction with a recombinant viral vaccine, e.g., a poxvirus vaccine, to potentiate and broaden the immune response. The present invention further provides a particularly effective vaccine regimen comprising a DNA vaccine used in combination with a poxvirus virus, especially NYVAC or ALVAC.

Claims

1. A method of potentiating a CD8⁺ response to human immunodeficiency virus-1 (HIV-1) epitopes in a human by adminstering a combination of vaccines, said method comprising:

administering a nucleic acid vaccine;

administering a recombinant pox virus vaccine encoding one or more of the same antigens encoded by the nucleic acid vaccine;

wherein the nucleic acid and the recombinant pox virus vaccines enter the cells of the human and intracellularly produce HIV-specific peptides that are presented on the cell'"'"'s MHC class I molecules in an amount sufficient to stimulate a CD8⁺ response, and further, wherein administration of the combination of vaccines potentiates the immune response compared to administration of either the nucleic acid or the recombinant pox virus vaccine by itself.

2. A method of claim 1 wherein the vaccine is an attenuated recombinant pox virus vaccine.

3. A method of claim 2 wherein the attenuated recombinant pox virus vaccine is selected from the group consisting of NYVAC and ALVAC.

4. A method of claim 1, wherein the nucleic acid vaccine is a DNA vaccine.

5. A method of claim 1 wherein the HIV-specific peptides are structural viral peptides

6. A method of claim 1 wherein the HIV-specific peptides are non-structural viral peptides.

7. A method of claim 1 wherein the vaccines further comprise an adjuvant.

8. A method of claim 1 further comprising two administrations of nucleic acid vaccine.

9. A method of claim 8 comprising three administrations of the nucleic acid vaccine.

10. A method of claim 1, wherein the nucleic acid vaccine is administered before the recombinant pox virus vaccine.

11. A method of claim 1, wherein the human is infected with HIV-1.

12. A method of claim 11, wherein the human has a viral load of less than 10,000 copies per milliliter.

13. A method of claim 1, wherien the human is not infected with HIV-1.